Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

93 results about "Adhesion protein" patented technology

Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers

The present invention relates to the discovery that biocompatible anionic polymers can effectively inhibit fibrosis, scar formation, and surgical adhesions. The invention is predicated on the discovery that anionic polymers effectively inhibit invasion of cells associated with detrimental healing processes, and in particular, that the effectiveness of an anionic polymer at inhibiting cell invasion correlates with the anionic charge density of the polymer. Thus the present invention provides a large number of materials for use in methods of inhibiting fibrosis and fibroblast invasion. Anionic polymers for use in the invention include but are not limited to natural proteoglycans, and the glycosaminoglycan moieties of proteoglycans. Additionally, anionic carbohydrates and other anionic polymers may be used. The anionic polymers dextran sulfate and pentosan polysulfate are preferred. In a more preferred embodiment, dextran sulfate, in which the sulfur content is greater than about 10% by weight, may be used. In a more preferred embodiment, the average molecular weight is about 40,000 to 500,000 Daltons. The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The invention further provides compositions and methods to inhibit glial cell invasion, detrimental bone growth and neurite outgrowth. In a preferred embodiment, the inhibitory compositions further comprise an adhesive protein.
Owner:TRIAD

Mycoplasma bovis gene mutation strain having reduced adhesion capacity and adhesion protein

The invention belongs to the technical field of prevention and treatment of animal borne diseases, and relates to a mycoplasma bovis gene mutation strain having reduced adhesion capacity and adhesionprotein. The protein gene Mbov_0503 is cloned from a mycoplasma bovis HB0801 genome. According to the partiality properties of escherichia coli to codons, the Mbov_0503 gene is modified, and mycoplasma bovis tryptophan codons UGA are mutated into codons UGG for coding tryptophan in the escherichia coli, so that recombination protein Mbov0503 is obtained. The nucleotide sequence of the protein geneis shown as SEQID NO:13, and the coded protein sequence is shown as SEQID NO:14. The mutation strain is the adhesion defect strain screened from a mutant library. Compared with wild strains, the mutation stain has the advantages that the adhesion capacity to host EBL cells, the cross-membrane transmission capacity to MDBK cells and destructivity to tight connection between cells of the mutation strain are notably reduced. The mycoplasma bovis gene mutation strain can be used for prevention and treatment of mycoplasma bovis diseases.
Owner:HUAZHONG AGRI UNIV

Fish and shrimp phagostimulant of famented product adhesion protein and its prepn process

The fish and shrimp phagostimulant of fermented product and adsorbed protein is prepared through screening beneficial bacteria seed from cultivated animal body, culturing in composite culture medium to proliferate, concentrating and adding plant protein with phagostimulant effect. It is added into fish and shrimp feed to raise their feed intake and improve their digesting function. The production process has combined beneficial microbe fermenting technology and low temperature drying technology to ensure the fast growth of beneficial bacteria, the well preservation of metabolic product and the special cultivating function. The fish and shrimp phagostimulant is one kind of green product capable of replacing traditional phagostimulant and antioxidant.
Owner:SHANGHAI CHUANGBO ECOLOGICAL ENG

Reagents for the detection of protein phosphorylation in carcinoma signaling pathways

The invention discloses nearly 474 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Kinase, Adaptor / Scaffold proteins, Phosphatase, G protein Regulator / Guanine Nucleotide Exchange Factors / GTPase Activating Proteins, Cytoskeleton Proteins, DNA Binding Proteins, Phospholipase, Receptor Proteins, Enzymes, DNA Repair / Replication Proteins, Adhesion Proteins, and Proteases, as well as other protein types.
Owner:CELL SIGNALING TECHNOLOGY

DNA array for high throughput solid-phase transfection and method for producing the same

The present invention relates to a DNA array for high throughput and highly efficient solid-based transfection which comprises a plurality of dried spots on a solid support, said dried spot comprises (1) a plasmid DNA to be introduced into cells, (2) a transfection reagent and (3) a cell-adhesion protein and to a high throughput and highly efficient solid-based transfection method to introduce plasmid DNA into cells, using the same.
Owner:THE SCRIPPS RES INST

Immobilization of biomolecules on substrates by attaching them to adsorbed bridging biomolecules

An assay article for detection first biomolecules contained in a sample is described. The assay article includes a substrate having a modified surface and a first biomolecule directly adsorbed and immobilized on the modified surface of the substrate without linking moieties. A second biomolecule is bound to or adsorbed on the first biomolecule. Also disclosed is a method of making the assay article. A first biomolecule (other than an adhesive protein) is contacted with a modified surface of a substrate. The substrate is dried to directly adsorb the first biomolecule and immobilize it on the modified surface of the substrate without additional fixing steps to form an activated substrate. Then, a second biomolecule is contacted with the activated substrate under conditions sufficient for the first biomolecule to bind the second biomolecule.
Owner:BECKMAN COULTER INC

Establishment and expression of fusion protein having function of adsorbing heavy metal ions, and application fusion protein in bioremediation

The invention discloses a preparation method of a fusion protein (SEQ ID No: 4) of a decamer containing a metal binding polypeptide and a connecting peptide, and a skin cell adhesion tripeptide, and an application of the fusion protein, especially an application of the fusion protein in the field of cosmetics. The preparation method disclosed by the invention is characterized by comprising the following steps of: obtaining a DNA sequence (SEQ ID No: 8) for coding the fusion protein of the decamer containing the metal binding polypeptide and the connecting peptide, and the skin cell adhesion tripeptide by virtue of a gene engineering technique, and then performing recombination expression by a surface display method in lactic acid bacteria. As the metal binding polypeptide and the skin cell adhesion protein have the abilities of binding harmful heavy metal ions and increasing the adhesive skin of an expression host, respectively, the cosmetics prepared from lactic acid engineering bacteria of the fusion protein of the decamer containing the metal binding polypeptide and the connecting peptide and the skin cell adhesion tripeptide expressed by the surface display method are capable of effectively reducing accumulation of toxic heavy metals in skin; and therefore, the effect of bioremediation is achieved.
Owner:GUANGZHOU BIO ZONE BIOTECH +1

Method for preparing novel mixing artificial blood vessel

The present invention discloses a method for preparing a novel mixing artificial blood vessel, which relates to a surface treatment of artificial blood vessel materials, and the object is to improve the adhesiveness of vascular smooth muscle cells and vascular endothelial cells. According to the present researches, the endothelialization of artificial blood vessel is considered a new direction for researching, but the monolayer endothelial cells on the inner surface of the artificial blood vessel are easy to partly lose under shearing force. According to the invention, 75% medical alcohol is instilled to increase the permeability of the artificial blood vessel and 0.01% fiber adhesion protein coating is used to increase the adhesiveness, in order to increase the adhesiveness of the blood vessel endothelial cells and the surface of the artificial blood vessel. Besides, blood vessel smooth muscle cells and blood vessel endothelial cells are respectively inoculated on the inner surface of the artificial blood vessel to construct an artificial blood vessel with better organism simulation. The method for preparing a novel mixing artificial blood vessel provided by the invention establishes the foundation for the subsequent development and exploitation of organization engineering artificial blood vessel having compositions and functions similar to a physiological artery.
Owner:THE STOMATOLOGIAL HOSPITAL OF ZHEJIANG UNIV SCHOOL OF MEDICINE

High throughput cardiotoxicity screening platform

InactiveUS20180106782A1Analyze loss of synchronicity of beatingEasy to holdUnknown materialsBiological testingHipsc cmsTraction force microscopy
Systems for assaying human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are provided. Aspects of the systems include a traction force microscopy substrate, such as a traction force microscopy hydrogel (TFM-hydrogel), having an adhesion protein domain on a surface thereof; a video imager configured to obtain video data from an hiPSC-CM present on the adhesion protein domain; and a processing module configured to receive the video data and derive a parameter of the hiPSC-CM therefrom. Also provided are methods of using the systems.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Highly bioactive extracellular matrix material and preparation method and application thereof

ActiveCN107823710AIn line with the law of regenerationAchieving functional restorationTissue regenerationProsthesisUltra high pressureCell-Extracellular Matrix
The invention relates to a highly bioactive extracellular matrix material and a preparation method and an application thereof. The material is prepared from raw materials with combined use of ultra-high pressure and cavity internal and external perfusion. The preparation method mainly includes the steps: raw material obtaining and preparation, and pretreatment; extracellular matrix mechanical separation; ultra-high pressure crushing and decellularizing; cell content elution and antigen elimination; and ultimately disinfection, sterilization and preservation. Compared with an extracellular matrix obtained by decellularizing through a mechanical oscillation method and a chemical reagent or biological reagent method, the extracellular matrix obtained by the preparation method has the retention amount of adhesion proteins, growth factors, proteoglycans, glycoproteins, glycosaminoglycans and other bioactive components significantly improved; at the same time, the mechanical strength is wellretained, the decellularizing is thorough, and viruses and other biological supporters are removed cleanly and industrialized production is convenient.
Owner:EXCELLENCE MEDICAL TECH SUZHOU CO LTD +2

Carbocyclic hydrazino inhibitors of copper-containing amine oxidases

The present invention is directed to carbocyclic hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-I (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The novel compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof wherein R1 to R11 are as defined herein.
Owner:BIOTIE THERAPIES CORP

Method for screening and identifying adhesion proteins

The invention provides a method for screening and identifying adhesion proteins. The method is characterized by comprising the following steps of: carboxylating superficial magnetic beads; processing the carboxylated magnetic beads by using carbodiimide and sulfo-hydroxysuccinimide; covalently coupling the magnetic beads with enterocyte debris to form amido bonds; after cleaning the magnetic beads, incubating the magnetic beads and probiotic surface protein solution together for one hour; washing the magnetic beads by using PBS buffer solution for three times to remove non-adhesion surface proteins; eluting the adhesion proteins by using 50 mM of glycine hydrochloric acid buffer solution of which the pH value is 2.3; and after SDS-PAGE electrophoresis, sequencing by mass spectrometry to identify the adhesion proteins. The method for screening and identifying the adhesion proteins has the advantages that: a magnetic bead method makes use of the characteristic that the adhesion proteins can adhere enterocyte to combine the function and separation into one step, so that the efficiency of screening the adhesion proteins is greatly improved, and the adhesion proteins can be efficiently screened and identified in a high-throughput mode; and compared with the conventional chromatography method, the method has the advantages of low cost, time saving, labor saving, and capacity of screening and identifying a plurality of adhesion proteins in one step.
Owner:NANCHANG UNIV

Macrophage vesicle entrapped nano-drug preparation and application thereof in treating arthritis

The invention belongs to the technical field of biology, relates to preparation of bionic nano-carriers and targeted treatment of arthritis, and particularly relates to a macrophage vesicle entrappednano-drug preparation and application thereof in treating arthritis. The nano-drug preparation targets an arthritis part through adhesive protein on the surface of a macrophage vesicle, and an immunosuppressive drug is delivered for targeted treatment of arthritis. Furthermore, a new strategy for targeted treatment of arthritis is provided for clinical practice, and the strategy comprises the steps of fusing an artificial drug carrier and the natural macrophage vesicle, and constructing the stable macrophage vesicle entrapped nano-drug preparation, thereby improving the targeted treatment effect of arthritis.
Owner:FUDAN UNIV

Preparation method of cartilage acellular matrix composite scaffold and application thereof

The invention belongs to the field of biomedical materials, and particularly relates to a preparation method of a cartilage acellular matrix composite scaffold and an application thereof. The structure of the cartilage acellular matrix composite scaffold is shown as a formula I, and the cartilage acellular matrix composite scaffold is a natural polymer or a derivative thereof and is a digested cartilage acellular matrix; wherein the mass percentage of the natural polymer or the derivative thereof is 25-75%, preferably 25-50%; wherein the mass percentage of the digested cartilage acellular matrix is 25-75%, preferably 50-75%. The invention discloses an acellular matrix / natural polymer composite material, after being implanted into a body, natural macromolecules or derivatives thereof are gradually degraded and absorbed in vivo, adhesion protein, growth factors and the like in acellular matrixes promote mesenchymal stem cells in bone marrow blood to differentiate into cartilage cells andmaintain the phenotype of the cartilage cells, the cartilage healing effect is effectively improved, a good operation curative effect is achieved, and the clinical application prospect is good.
Owner:SICHUAN UNIV

Macroporous bioengineered scaffolds for cell transplantation

InactiveUS20130089594A1Hindering nutrient deliveryImprove viabilityBiocidePancreatic cellsCell adhesionInsulin producing cell
The present invention provides highly porous, biocompatible and biostable scaffold constructs for improving overall cell engraftment, survival, function and long-term viability. These scaffolds can provide mechanical protection to implanted cells, afford retrievability from a subject, and allow for both intra-device vascularization and a means to spatially distribute the cells within the device. The scaffold surface or material may be modified with one or more different adhesion proteins and optionally other biological factors for enhanced cell adherence and viability. Further, the scaffold surface or material may be modified with one or more agents with slow / sustained release characteristics to aid engraftment, survival, function or long-term viability. Implanted cells of the invention may be insulin-producing cells such as islets.
Owner:CONVERGE BIOTECH INC +1

Methods and compositions for inhibiting tumor growth and angiogenesis

The invention provides compositions comprising angiogenesis inhibitors and RGD-containing plasma adhesion proteins in a pharmaceutical carrier. This invention also provides methods of inhibiting angiogenesis, tumor growth and metastasis by administering angiogenesis inhibitors in combination with RGD-containing plasma adhesion proteins in a pharmaceutical carrier.
Owner:RUSHTI ERKKI

Method for separating and purifying mussel adhesive protein

Provided is a method for separating and purifying a mussel adhesive protein, including the steps of: (1) crushing cells containing a mussel adhesive protein; (2) centrifuging the crushed cells to obtain an insoluble protein aggregate including the mussel adhesive protein; (3) treating the insoluble protein aggregate with an acidic organic solvent to obtain a low-purity mussel adhesive protein solution; (4) selectively precipitating the mussel adhesive protein by controlling the acidity of the low-purity mussel adhesive protein solution; and (5) treating the precipitate with a surfactant to remove endotoxins from the mussel adhesive protein. The method of the subject matter can purify a large amount of mussel adhesive proteins of high purity with a simple process. In particular, the subject matter can be applied effectively to the development of novel uses of mussel adhesive proteins by significantly reducing production costs through economical production of the mussel adhesive protein.
Owner:KOLLODIS BIOSCI

Reagens for the Detection of Protein Acetylation Signaling Pathways

The invention discloses 432 novel acetylation sites identified in signal transduction proteins and pathways underlying human protein acetylation signaling pathways, and provides acetylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these acetylated sites / proteins, as well as methods of using the reagents for such purpose. Among the acetylation sites identified are sites occurring in the following protein types: Acetyltransferases, Adaptor / Scaffold proteins, Actin binding proteins, Adhesion proteins, Apoptosis proteins, Calcium-binding proteins, Cell Cycle Regulation proteins, Cell Surface proteins, DNA binding proteins, DNA replication proteins, Channel proteins, Chaperone proteins, Cellular Metabolism enzymes, Cytoskeletal proteins, DNA repair proteins, Endoplasmic reticulum proteins, Enzyme proteins, G protein and GTPase Activating proteins, Guanine Nucleotide Exchange Factors, Helicase proteins, Isomerase proteins, Extracelluar matrix proteins, Hydrolases, Ligase proteins, Lipid kinases, Inhibtor proteins, Lipid Binding proteins and Lyases.
Owner:CELL SIGNALING TECHNOLOGY

Application of Src kinase inhibitor in preparing medicaments for treating acute kidney injury

The invention provides application of Src kinase inhibitor in preparing medicaments for treating acute kidney injury. Further, the acute kidney injury is caused by renal ischemia. Further, the Src kinase inhibitor is PP1 (4-Amino-5-(methylphenyl)-7-(t-butyl)pyrazolo-(3,4-d)pyrimidine). The invention proves that PP1 inhibition of Src can relieve the pathobiological change of kidney after I / R, so as to improve kidney function. The treatment mechanism of the Src kinase inhibitor includes procedures of inhibiting apoptosis of renal tubule cells, protecting multiple connexins and adhesive proteins, and inhibiting cell death and inflammation signal pathway.
Owner:SHANGHAI EAST HOSPITAL

High adhesion clostridium butyricum and its preparation method

The invention discloses high adhesion clostridium butyricum and its preparation method, and belongs to the field of gene recombination. The invention provides the high adhesion clostridium butyricum and its preparation method to solve the technical problem, the main points of the technical proposal are that lactobacillus adhesion protein gene is obtained by cloning, and a lactobacillus adhesion protein gene-containing recombinant plasmid is converted into clostridium butyricum by use of a gene recombination method to obtain a clostridium butyricum recombinant strain. Through gene expression, the clostridium butyricum is capable of autologous production of a protein with the adhesion function, the adhesion ability is greatly improved, and the efficacy of the treatment of the clostridium butyricum is further improved.
Owner:OCEAN UNIV OF CHINA

Coacervate having an ionic polymer mixed with the adhesive protein of a mussel or of a species of the variome thereof

The present invention relates to a coacervate comprising a mussel adhesive protein and an anionic polymer, and more particularly, to a coacervate prepared by mixing a mussel adhesive protein with an anionic polymer, and a novel use thereof. In the present invention, a coacervate prepared by mixing a mussel adhesive protein and an anionic polymer shows a very excellent adhesive strength to various substrates such as cells or metals, and is able to maintain its adhesive strength in the presence of water or under water, thereby being effectively used as an adhesive. Moreover, it has an activity capable of encapsulating bioactive materials, thereby being effectively used as an active component of a composition for delivering bioactive materials.
Owner:POSTECH ACAD IND FOUND

Reagents for the detection of protein phosphorylation in carcinoma signaling pathways

The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine / Threonine dual specificity, and Tyrosine kinases), Adaptor / Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators / GTPase activating protein / Guanine nucleotide exchange factor proteins, and DNA binding / replication / repair proteins, as well as other protein types.
Owner:CELL SIGNALING TECHNOLOGY

Diblock fusion protein with adhesion-antifreeze dual functions, and synthesis method and application thereof

The invention relates to a diblock fusion protein with adhesion-antifreeze dual functions, and a synthesis method and application thereof. By taking genetic engineering as a technological means, a gene expression vector simultaneously containing antifreeze protein genes and adhesion protein genes is prepared and converted into a host cell, through an inducer, the host cell overexpresses the protein, and thus the fusion protein is obtained by separation and purification. The amino acid sequence of the fusion protein is SEQ ID NO.3, and the nucleotide sequence of the fusion protein is SEQ ID NO.4. The mussel adhesion protein and the antifreeze protein are fused on the gene level, and thus the diblock fusion protein with the adhesion-antifreeze dual functions is constructed; and the fusion protein is expressed through fermentation of escherichia coli, supernatant protein is purified through an affinity chromatogram, an inclusion body is purified through acetic acid, a high-purity separation and purification method is constructed, the fusion protein is synthesized through a microbial one-step method, the process is mild and efficient, the cost is low, the equipment requirement degree is low, and expanded production at the later period is easy.
Owner:TIANJIN UNIV

Haemophilus adhesion proteins

The invention relates to novel Haemophilus adhesion proteins, nucleic acids, and antibodies.
Owner:WASHINGTON UNIV IN SAINT LOUIS +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products